The power and potential of doxorubicin-DNA adducts
- PMID: 16036566
- DOI: 10.1080/15216540500079093
The power and potential of doxorubicin-DNA adducts
Abstract
Doxorubicin (trade name Adriamycin) is a widely used anticancer agent which exhibits good activity against a wide range of tumors. Although the major mode of action appears to be normally as a topoisomerase II poison, it also exhibits a number of other cellular responses, one of which is the ability to form adducts with DNA. For adduct formation doxorubicin must react with cellular formaldehyde to form an activated Schiff base which is then able to form an aminal (N-C-N) linkage to the exocyclic amino group of guanine residues. The mono-adducts form primarily at G of 5'-GCN-3' sequences where the chromophore of the drug is intercalated between the C and N base pair. The structure of the adducts has have been well defined by 2D NMR, mass spectrometry and X-ray crystallography. The formation of these anthracycline adducts in cells grown in culture has been unequivocally demonstrated. The source of formaldehyde in cells can be endogenous, provided by coadministration of prodrugs that release formaldehyde or by prior complexation of anthracyclines with formaldehyde. Since the adducts appear to be more cytotoxic than doxorubicin alone, and also less susceptible to drug-efflux forms of resistance, they offer new approaches to improving the anticancer activity of the anthracyclines.
Similar articles
-
Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.Cancer Res. 2006 May 1;66(9):4863-71. doi: 10.1158/0008-5472.CAN-05-3410. Cancer Res. 2006. PMID: 16651442
-
DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair.Mutat Res. 2008 Feb 1;638(1-2):110-21. doi: 10.1016/j.mrfmmm.2007.09.005. Epub 2007 Sep 16. Mutat Res. 2008. PMID: 17961607
-
Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.J Med Chem. 1997 Apr 11;40(8):1276-86. doi: 10.1021/jm960835d. J Med Chem. 1997. PMID: 9111302
-
Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.Curr Top Med Chem. 2015;15(14):1409-22. doi: 10.2174/1568026615666150413154512. Curr Top Med Chem. 2015. PMID: 25866273 Review.
-
Barminomycin, a model for the development of new anthracyclines.Anticancer Agents Med Chem. 2010 Jan;10(1):70-7. doi: 10.2174/1871520611009010070. Anticancer Agents Med Chem. 2010. PMID: 19807684 Review.
Cited by
-
Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.Chem Res Toxicol. 2018 Oct 15;31(10):1042-1051. doi: 10.1021/acs.chemrestox.8b00107. Epub 2018 Sep 10. Chem Res Toxicol. 2018. PMID: 30152692 Free PMC article.
-
Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients.BMC Vet Res. 2021 Dec 7;17(1):378. doi: 10.1186/s12917-021-03062-x. BMC Vet Res. 2021. PMID: 34876121 Free PMC article.
-
Chlorotoxin-conjugated graphene oxide for _targeted delivery of an anticancer drug.Int J Nanomedicine. 2014 Mar 18;9:1433-42. doi: 10.2147/IJN.S58783. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24672236 Free PMC article.
-
Anti-Proliferative Effect of Doxorubicin-Loaded AS1411 Aptamer on Colorectal Cancer Cell.Asian Pac J Cancer Prev. 2021 Jul 1;22(7):2209-219. doi: 10.31557/APJCP.2021.22.7.2209. Asian Pac J Cancer Prev. 2021. PMID: 34319045 Free PMC article.
-
Managing sarcoma: where have we come from and where are we going?Ther Adv Med Oncol. 2017 Oct;9(10):637-659. doi: 10.1177/1758834017728927. Epub 2017 Sep 20. Ther Adv Med Oncol. 2017. PMID: 28974986 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
